SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins sharp selloff and break below a key psychological support level are driving attention, with traders citing heavy selling and leveraged long liquidations. Bearish calls for a deeper correction compete with dip-buying and bear-trap arguments from bulls.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is drawing attention ahead of its upcoming earnings report, with traders focused on margin guidance and whether the business can sustain its recent momentum near record highs. The community is split between bullish breakout views and concerns that the stock is overbought and could pull back if guidance disappoints.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express shares are under pressure despite an earnings beat and higher full-year guidance, as traders focus on planned workforce reductions and restructuring costs. The debate is whether those charges and a slight revenue shortfall outweigh resilient card spending and stronger profit expectations; some investors view the selloff as an overreaction.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention amid volatile natural-gas futures and debate over whether winter weather and tighter storage can lift prices or whether mild forecasts, strong production, and ample supply will keep pressure on them. Bulls are looking for a seasonal rebound, while skeptics emphasize BOILs leverage, futures-roll costs, and daily decay as risks to holding it through the swings.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Early Phase 1 azer-cel results in progressive multiple sclerosis are drawing attention, with traders viewing the safety and disability-stabilization signals as encouraging but emphasizing the small, uncontrolled study. Some see it as adding pipeline value beyond BRIUMVI, while others say the market response has been muted and are focused on upcoming subcutaneous BRIUMVI data and earnings; buyout talk remains speculative.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Colas stronger-than-expected quarterly results and raised full-year outlook, supported by volume growth, have fueled a rally and renewed interest in the stock as a defensive holding. Traders are broadly bullish on the earnings momentum, while others argue the valuation is stretched and the run may be due for a pullback.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Reported Phase 3 results for Mercks Keytruda combination with Modernas personalized melanoma vaccine are driving attention: the treatment reduced the risk of recurrence or death, but the results fell short of some traders higher expectations. The community is split between viewing the data as a meaningful cancer-vaccine advance and a sell-the-news disappointment, with Merck shares under pressure alongside Moderna.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercards upcoming quarterly report is the main focus, with traders weighing the earnings outlook after a strong run toward record highs. Bullish posts highlight the breakout and resilient payment trends, while cautious traders point to weakness across card stocks and American Expresss results as reasons for caution.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs reported founder and CMO departures to start a separate biotech, alongside a weak outlook, are driving concerns about leadership and the companys direction. Traders are divided: bears cite execution risks and oncology setbacks, while bulls point to the cash position and late-stage pipeline.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Elevated oil prices and supply-disruption fears tied to Middle East tensions, including risks to Strait of Hormuz shipping and energy infrastructure, are underpinning strength in the energy sector. Traders highlight XLEs breakout and record highs, while others warn of overextension, volatile headlines, and at times a disconnect between crude and energy shares.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining in pre-market trading.read more...

Why Did TRAW Stock Slump 28% After Hours?

Equity

Traws is delaying a planned human study of its lead flu treatment, tivoxavir marboxil, after feedback from a UK regulator.

Do Not Ignore this Rally

The market is currently witnessing a rare phenomenon: a synchronized breakout across the small-cap and emerging growth sectors. While mega-cap tech grabs the headlines, the real alpha is being generated by innovators in energy, space, and biotech. As we head into the closing bell and the crucial after-hours session, momentum is building in names that are fundamentally shifting their industries. $INTC, $RXT, $BB, $TRAW, $XERI, $RDW

A Hantavirus Update Has Sent This Nano-Cap Biotech Stock Surging Today – Here’s Why Retail Sees Potential 20x Gains

Traws Pharma, which develops antiviral drugs, said it plans to advance potential clinical candidates for the treatment of hantavirus infections.

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?

The company announced the completion of enrollment in its Phase 2 trial of Ratutrelvir, an investigational oral antiviral for mild-to-moderate COVID-19.

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.read more...

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials ChemDiv Extends CMC Services Collaboration for...

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. Dover...

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Reported GAAP EPS of -$0.16 down -45.45% YoY

Traws Pharma faces significant challenges including a clinical hold on its lead program, absence of revenue, and potential future liquidity constraints necessitating additional financing to support operations beyond early 2027.

Traws Pharma is progressing its lead influenza candidate toward MHRA resubmission while securing potential financing of up to $50 million and expanding its platform capabilities into other emerging viral threats.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Traws Pharma Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>The company emphasized that it maintains a portfolio of backup influenza antiviral compounds and is actively advancing alternative candidates.</li><li>The Food and Drug Administration placed the company’s Investigational New Drug (IND) application for tivoxavir marboxil earlier this year.&nbsp;</li><li>According to data from Koyfin, both the analysts covering TRAW rate it a ‘Buy.’</li></ul>Shares of Traws Pharma (TRAW) fell about 28% in after-hours trading on Friday after the company said it is delaying a key study for its experimental flu drug.The company announced it is putting off a planned human study for its lead flu treatment, tivoxavir marboxil, after receiving feedback from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).Under the trial, slated to begin this quarter, healthy volunteers would have received either the drug or a placebo and then been exposed to a controlled strain of the influenza virus. Researchers would then gauge whether the drug prevented an infection.<h2 class="st-heading-2">Traws Still Sees Strong Potential For Bird Flu Treatment</h2>Traws said it is stepping back from the study for now while it works on addressing the regulators’ concerns. The company still believes the drug has potential, especially for treating or preventing serious bird flu infections.“Tivoxavir marboxil demonstrated potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile consistent with its use for bird flu treatment and prevention,” said the company’s Chief Science Officer, David Pauza. “The product candidate retains potential for emergency use in a bird flu outbreak and for prevention in high-risk populations.”The company emphasized that it maintains a portfolio of backup influenza antiviral compounds and is actively advancing alternative candidates. The company has a cash runway extending into the first quarter of 2027.“While we have had a setback in the development of our lead compound for influenza, the program continues to be a high priority,” said Chief Medical Officer Robert R. Redfield.<h2 class="st-heading-2">U.S. Clinical Trials Also On Hold</h2>Meanwhile, clinical trials of the drug are also on hold in the U.S. The Food and Drug Administration placed the company’s Investigational New Drug (IND) application for tivoxavir marboxil on hold shortly after Traws filed it in mid-January. The hold stems from concerns about the toxicology data package, particularly around the potential to cause genetic changes.In February, the company said it was preparing a response to address the regulator’s concerns, without which it cannot commence clinical trials.<h2 class="st-heading-2">How Did TRAW Retail Traders React?</h2>On Stocktwits, retail sentiment around TRAW rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume improved from ‘extremely low’ to ‘low’ levels.A Stocktwits user dismissed the after-hours drop as “overblown.”<stembedurl>https://www.stocktwits.com/AshleySchaeffer_BMW/message/656347866</stembedurl>According to data from Koyfin, both the analysts covering TRAW rate it a ‘Buy.’ The stock has an average 12-month price target of $5.5, implying a potential upside of over 300% from the stock’s last close.<a href="https://stocktwits.com/symbol/TRAW">TRAW stock</a> has fallen 4% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dnth-stock-clocks-best-day-in-over-3-months-on-strong-nerve-disorder-study-results/cZKd9QHR75h">DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of biopharma company Traws Pharma Inc. is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Vanguard Extended Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$TRAW they try to bring this down PM and AH. Brought it down to 0.46 last night. I dare you to do it again and I’ll just accumulate more. This one is a no brainer at these lows with catalyst coming any day.

Winston

$TRAW Oof... chart looked like it was trying to play again and then it just started melting.

Brian Badtrader

$TRAW 💰 

On October 23, 2026, Traws Pharma, Inc. entered into a common stock purchase agreement with Roth Principal Investments, LLC, granting Traws the right to sell up to $50,000,000 of newly issued common stock under a related registration rights agreement. 

Prioritized by relevance

Feed

News

Sentiment

Earnings

Fundamentals

Info

TRAW Traws Pharma Inc.

Fundamentals

Latest TRAW News